GlassScriptPhysician profile
Davendra Mehta
NPI 1326084971
$37,635.80
in general payments reported to CMS, 2019-2025
27 companies · $2,642 in 2025
The $2,642 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $25K · 2021: $1,684 · 2022: $757 · 2023: $552 · 2024: $5,489 · 2025: $2,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,954 · Food and Beverage: $3,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,954.35 |
| Food and Beverage | $3,729.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $25,049.41 | 2019-2020 | |
| Boston Scientific Corporation | $4,796.64 | 2019-2025 | Ingevity+, Farapulse, Ingevity Mri |
| Abbott Laboratories | $4,427.68 | 2019-2025 | Aveir, Amplatzer Amulet, Ensite |
| Medtronic, INC. | $781.59 | 2021-2025 | Linq II, Pulseselect, Micra |
| Stereotaxis INC | $738.34 | 2019-2022 | |
| Biosense Webster, INC. | $599.14 | 2019-2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $223.34 | 2020-2025 | Camzyos |
| Philips North America LLC | $126.10 | 2021-2023 | |
| Cardiva Medical, INC. | $103.37 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $103.26 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $78.65 | 2020-2024 | Xarelto |
| Scpharmaceuticals INC. | $73.47 | 2024-2025 | |
| Amgen INC. | $67.63 | 2020-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $61.78 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $57.17 | 2024-2025 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baylis Medical Company INC | $47.45 | 2021 | |
| Cordis US Corp. | $40.70 | 2025 | Mynx Control Venous |
| Kestra Medical Technology Services, INC. | $40.24 | 2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $36.53 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.68 | 2024 | Jardiance |
| Angiodynamics, INC. | $29.07 | 2025 | Alphavac |
| Lantheus Medical Imaging, INC. | $28.25 | 2019 | |
| Alcresta Therapeutics, INC. | $26.47 | 2025 | Relizorb |
| Kiniksa Pharmaceuticals International, Plc | $22.29 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.85 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.70 | 2025 | Wainua |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davendra Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.